Implants News and Research

RSS

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Pervasis Therapeutics, Inc. today announced that the company is pursuing a matrix-embedded endothelial cell-based therapy (PVS-30200) to target and regulate cell stroma (the tumor environment or "ecosystem" that is comprised of various supporting cell types distinct from cancer cells) in order to prevent key processes that play a role in advancing solid tumor growth and metastasis.

20 Jan 2011

Endothelial cells may play a role in controlling cancer behavior: New study

MIT scientists have discovered that cells lining the blood vessels secrete molecules that suppress tumor growth and keep cancer cells from invading other tissues, a finding that could lead to a new way to treat cancer.

20 Jan 2011

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Maintaining periodontal health may contribute to a healthy respiratory system, according to research published in the Journal of Periodontology. A new study suggests that periodontal disease may increase the risk for respiratory infections, such as chronic obstructive pulmonary disease (COPD) and pneumonia.

19 Jan 2011

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

Medtronic, today announced it has received conditional approval from the U.S. Food and Drug Administration to modify its CoreValve U.S. Pivotal Clinical Trial.

19 Jan 2011

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

According to Millennium Research Group, the global authority on medical technology market intelligence, the prosperity of the US market for orthopedic extremity devices will be bolstered by continued product innovation and surgeon specialization. Despite sluggish economic performance in the US market and impending regulatory changes imposed by health care reform, the US orthopedic extremity device market will generate over $4.6 billion in revenues by 2015, growing at a compound annual growth rate in excess of 10%.

18 Jan 2011

Zimmer launches LPS-Flex Mobile Bearing knee system in the US

Zimmer Holdings, a global leader in musculoskeletal care, today launched the Zimmer NexGen LPS-Flex Mobile Bearing Knee with Prolong Highly Crosslinked Polyethylene in the United States.

14 Jan 2011

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

FibroGen, Inc. today announced initiation of an open-label phase 2 study to evaluate the safety, tolerability, and efficacy of FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), in individuals with idiopathic pulmonary fibrosis (IPF), a chronic, progressive, fatal lung disease for which there are no FDA-approved therapies.

13 Jan 2011

Dream team to build mind-controlled prosthetic devices

University of Houston researchers are helping the Pentagon build reliable mind-controlled prosthetic devices that military and civilian amputees can use the rest of their lives.

12 Jan 2011

Hybrid cochlear implant may benefit patients with profound hearing loss

Northwestern Memorial Hospital is one of nine centers in the U.S., and the only in Illinois, that is participating in a study investigating the effectiveness of a new cochlear implant device that aims to restore hearing for individuals with high-frequency hearing loss and functional low-frequency hearing.

12 Jan 2011

How chlamydia increases risk of ectopic pregnancy

Women who have had chlamydia are at greater risk of an ectopic pregnancy because of a lasting effect of the infection.

11 Jan 2011

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

Abbott announced today that it has received CE Mark approval for the world's first drug eluting bioresorbable vascular scaffold (BVS) for the treatment of coronary artery disease. Abbott's BVS device restores blood flow by opening a clogged vessel and providing support to the vessel until the device dissolves within approximately two years, leaving patients with a treated vessel free of a permanent metallic implant. Abbott's BVS device will be commercialized under the brand name ABSORB.

10 Jan 2011

MAKO sells 13 Robotic Arm Interactive Orthopedic Systems during fourth quarter 2010

MAKO Surgical Corp., a medical device company that markets both its RIO® Robotic Arm Interactive Orthopedic surgical platform and proprietary RESTORIS® implants for minimally invasive orthopedic procedures known as MAKOplasty®, today announced its selected operating results for its fourth quarter ended December 31, 2010

10 Jan 2011

22.5% implanted defibrillators are unnecessary: Study

According to a new study nearly 20% of American patients who receive an implantable cardioverter-defibrillator (ICD) may not need it. These ICDs when unnecessary could put the patients at higher risk of death and serious complications than patients who meet the criteria for the life-saving device say authors of the study published in the Jan. 5 issue of the Journal of the American Medical Association.

6 Jan 2011

Problems reported with Implanon contraceptive implant

Quite a few women have reported accidental and unwanted pregnancies while using Implanon, a hormone implant injected into the arm which is designed to last three years. Although the hormonal implant is described to be 99% effective, is thought to be due to problems with the initial implantation, rather than its efficacy once correctly inserted beneath the skin.

6 Jan 2011

MiMedx Group acquires Surgical Biologics

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected biomaterial-based products, announced today the completion of the purchase of Surgical Biologics, a leader in the development of tissue processing techniques for creating implants for a variety of surgical indications from amnion membranes.

6 Jan 2011

Researchers regenerate complete shoulder joint surfaces using patient's own cells

Artificial joint replacements can drastically change a patient's quality of life. Painful, arthritic knees, shoulders and hips can be replaced with state-of-the-art metal or ceramic implants, eliminating pain and giving a person a new lease on life.

6 Jan 2011

ODS enters license agreement with Enox Biopharma to develop novel treatment for periodontal disease

Enox Biopharma, a leader in the development of innovative solutions for infections associated with medical devices, and Ortho Dental Solutions LTD today announced an execution of an exclusive royalty bearing license agreement under which Enox Biopharma shall grant Ortho Dental Solutions LTD rights to patent application and knowhow for use in developing novel therapies limited in use for dental and gum diseases.

6 Jan 2011

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

A study that included more than 100,000 patients who received implantable cardioverter-defibrillators (ICDs) found that about 20 percent did not meet evidence-based guidelines for receipt of an ICD, and that these patients had a significantly higher risk of in-hospital death than individuals who met criteria for receiving an ICD, according to a study in the January 5 issue of JAMA.

5 Jan 2011

STAAR Surgical exceeds 200,000 Visian ICL global implants

STAAR Surgical Company, a leading developer, manufacturer and marketer of minimally invasive ophthalmic products, today announced that the worldwide total number of Visian® ICL implants in patients has exceeded 200,000. Since 1994, STAAR's Implantable Collamer® Lenses (ICLs) have been used in refractive eye surgery as an alternative to LASIK. Manufactured with STAAR's proprietary Collamer material, Visian ICLs provide a safe and effective alternative in the permanent correction of myopia, hyperopia, and in the case of the Toric ICL, astigmatism.

4 Jan 2011

Stryker closes acquisition of Boston Scientific Neurovascular

Stryker Corporation announced today the closing of its previously announced acquisition of the assets of the Neurovascular division of Boston Scientific, the global leader in the approximately $900 million worldwide neurovascular market, which includes products used for the minimally invasive treatment of hemorrhagic and ischemic stroke.

From Stryker 4 Jan 2011

Implants News and Research

Pervasis pursues matrix-embedded endothelial cell-based therapy to target and regulate cell stroma

Endothelial cells may play a role in controlling cancer behavior: New study

Healthy teeth and gums may reduce risk for pneumonia, chronic obstructive pulmonary disease

Medtronic recieves conditional approval from FDA to modify CoreValve U.S. Pivotal Clinical Trial

US market for orthopedic extremity devices to grow at 10% CAGR to $4.6 billion by 2015

Zimmer launches LPS-Flex Mobile Bearing knee system in the US

FibroGen initiates FG-3019 open-label phase 2 study in idiopathic pulmonary fibrosis

Dream team to build mind-controlled prosthetic devices

Hybrid cochlear implant may benefit patients with profound hearing loss

How chlamydia increases risk of ectopic pregnancy

World's first drug eluting bioresorbable vascular scaffold receives CE Mark approval

MAKO sells 13 Robotic Arm Interactive Orthopedic Systems during fourth quarter 2010

22.5% implanted defibrillators are unnecessary: Study

Problems reported with Implanon contraceptive implant

MiMedx Group acquires Surgical Biologics

Researchers regenerate complete shoulder joint surfaces using patient's own cells

ODS enters license agreement with Enox Biopharma to develop novel treatment for periodontal disease

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

STAAR Surgical exceeds 200,000 Visian ICL global implants

Stryker closes acquisition of Boston Scientific Neurovascular

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News